Scientific Advisory Committee (SAC)
The SAC serves as the chief advisory group for NBDA leadership relative to scientific and technical issues and questions in all phases of biomarker discovery and development. This group plays a key role in determining workshop needs in the biomarker development areas targeted by the NBDA; prioritizes and makes specific recommendations for solutions oriented actions from workshops and other sources (including, but not limited to, demonstration projects); and reviews results before publication and/or finalization of guidelines/standards/best practices, etc. The SAC is made up of experts who span the continuum of biomarker discovery and development through clinical trials and regulatory science and policy.
NBDA Scientific Advisory Committee
Laura van’t Veer, PhD CHAIR
Professor, Department of Laboratory Medicine, Helen Diller Family Comprehensive Cancer Center; Angela and Shu Kai Chan Endowed Chair in Cancer Research; Leader, Breast Oncology Program; and Director, Applied Genomics, University of California, San Francisco
Dr. van ‘t Veer is a world-renowned molecular biologist, former Head of Diagnostic Oncology at the Netherlands Cancer Institute, and inventor of MammaPrint. She is the leader of the Breast Oncology Program in the Helen Diller Family Comprehensive Cancer Center and a convenor of UCSF’s Precision Medicine Platform. Dr. van ‘t Veer’s research focuses on personalized medicine, to ensure that patient management is based on knowledge of the genetic make-up of the tumor as well as the genetic make-up of the patient. This allows practitioners to optimally assign systemic therapy for those patients that are in need of such treatment and to ensure the selection of the therapy that is most effective. Dr. van ‘t Veer’s research shows that molecular diagnostics and microarray genomics technology increasingly impacts patient management. Molecular genomics contributes to the knowledge of who is at risk for breast cancer, how external factors may influence this risk, whether breast tumors are likely to metastasize or not, and which subtype of tumors will likely respond to what therapy.
Karen Anderson, MD, PhD
Senior Associate Director, The Biodesign Institute, Associate Professor, School of Life Sciences Arizona State University
Dr. Anderson obtained her M.D. and Ph.D. degrees at Duke University and her clinical hematology/oncology training at the Dana Farber Cancer Institute in Boston, where she was a faculty member until 2011. She is a translational research scientist and Associate Professor at the Biodesign Institute at Arizona State University and Mayo Clinic Arizona. Dr. Anderson has extensive experience in the clinical translation of novel experimental diagnostics and therapeutics for cancer. Her laboratory has developed novel biomarkers for the early detection of breast, ovarian, and HPV-associated cancers. Dr. Anderson is co-chair of the NCI/Early Detection Research Network’s Breast/Gyn Collaborative Group and is principal investigator of a national study of biomarkers for triple negative breast cancer.
Michael E. Berens, PhD
Deputy Director, T-Gen Research Resources; Director, Cancer and Cell Biology Division; Professor, Brain Tumor Unit, Translational Genomics Research Institute
In additional roles at the Translational Genomics Research Institute (TGen), Dr. Berens serves as director of the Cancer and Cell Biology Division and Professor and head of the Brain Tumor Laboratory Unit. He was a member of Governor Jane Dee Hull’s 2002 Taskforce on Genomics, which developed strategies for the funding, partnerships, and recruitment that launched TGen. Dr. Berens’ academic career has included appointments at the University of Zurich, the Bowman Gray School of Medicine of Wake Forest University, the University of California, San Francisco, and the Barrow Neurological Institute.
At the Barrow Institute, he served for 12 years as Senior Investigator and Director of neurology research. Dr. Berens is pursuing a translational research program in brain tumor research that includes preclinical therapy development, novel treatment target discovery, and the study of malignant cell motility. His research program includes collaborations with Barrow Neurological Institute, Mayo Clinic, multi-institutional consortia, and international laboratories in Seoul, Tokyo, Sydney, and Bergen (Norway). Dr. Berens’ current research is funded by the NIH and private medical foundations. He holds four patents and is the founder of two for-profit ventures: Creative Scientific Methods Inc. and Avolix Pharmaceuticals, Inc. Dr. Berens serves on the editorial boards of several scientific journals and on committees that support governmental agencies, professional societies, and nonprofit organizations. He is also active in the technology and public policy sectors and is past chairman of the Arizona Technology Council. Dr. Berens received his Ph.D. degree from the University of Arizona.
Donald A. Berry, PhD
Founder and Senior Statistical Scientist, Berry Consultants, LLC, and Professor, Department of Biostatistics, The University of Texas M.D. Anderson
Dr. Berry is a professor in the Department of Biostatistics at The University of Texas M.D. Anderson Cancer Center. He was founding chair of this department in 1999 and founding head of the Division of Quantitative Sciences, including the Department of Bioinformatics and Computational Biology, in 2006. Dr. Berry received a Ph.D. degree in statistics from Yale University and previously served on the faculties of the University of Minnesota and Duke University. He held endowed faculty positions at Duke University and at M.D. Anderson. Since 1990 Dr. Berry has served as a faculty statistician on the Breast Cancer Committee of the Cancer and Leukemia Group B, a national oncology group. He has designed and supervised the conduct of many large U.S. intergroup trials in breast cancer. A principal focus of Dr. Berry’s research is the use of biomarkers in cancer and other diseases for learning which patients benefit from which therapies, based on genomics and phenotype. He designed and is a co-principal investigator of I-SPY 2 (www.ispy2.org), a Bayesian adaptive platform clinical trial in high-risk early breast cancer whose goal is matching experimental therapies with patient subsets defined by tumor molecular characteristics. Since 1997 Dr. Berry has served on the NCI’s PDQ Screening and Prevention Board, for which he received the NIH Award of Merit in 2010. Through Berry Consultants, LLC, he has designed many innovative clinical trials for pharmaceutical and medical device companies and for NIH cooperative groups. Dr. Berry is the author of several books on statistical methodology and over 300 published articles, including first-authored articles in the major medical journals. He has been the principal investigator for numerous research grants from the NIH and the National Science Foundation and is a fellow of the American Statistical Association and the Institute of Mathematical Statistics.
Michael A. Gillette, MD, PhD
Research Fellow, Proteomics and Biomarker Discovery Platform, Broad Institute, Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital
As a practicing pulmonary and critical care physician at the Massachusetts General Hospital, Dr. Gillette has been motivated by the largely phenomenological diagnoses of many disease states, the general lack of “actionable” molecular taxonomies of disease, and the dearth of markers for early disease detection or therapeutic monitoring to develop expertise in the development and application of MS identity- and pattern-based biomarkers. He leads Broad Institute efforts in cancer proteomic biomarker discovery, serving as Broad Co-PI (with Dr. Steven Carr) on a multi-institutional breast cancer biomarker discovery and verification project jointly supported by the Entertainment Industry Foundation Women’s Cancer Research Fund and Komen for the Cure; heading the proteomic effort on a multi-institutional EDRN-sponsored ovarian cancer program (Steve Skates, MGH, program PI); and maintaining a leadership role in the NCI-sponsored Clinical Proteomics Tumor Analysis Consortium (CPTAC) program that has undertaken to provide deep proteomic and phosphoproteomic annotation of breast, colon, and ovarian cancer samples previously genomically characterized as part of The Cancer Genome Atlas. Dr. Gillette’s biomarker development work extends beyond cancer to infectious diseases of high international health import, including Gates foundation-supported studies in tuberculosis and pediatric febrile illness. With other Broad colleagues, he has been involved in the development and implementation of all aspects of a coherent biomarker discovery-to-verification pipeline, including abundant protein depletion, chromatographic fractionation, unbiased discovery MS analysis, AIMS analysis for qualification of candidate biomarkers, and MRM- and SISCAPA-based candidate verification. Dr. Gillette holds MD and PhD (neurophysiology) degrees from Harvard University, an MSc (human biology) degree, and an MA degree (psychology and philosophy) from Oxford University, Oxford, United Kingdom. He brings a blend of clinical knowledge and current practice, experimental design, mass spectrometry, and diverse laboratory skills and over 9 years’ direct experience to his leadership roles in proteomic biomarker development.
Steven I. Gutman, MD, MBA
Strategic Advisor, Myraqa, Inc.
Dr. Gutman is a board-certified pathologist with a B.S. degree from The Ohio State University, an M.D. degree from Cornell University Medical College, and an M.B.A. degree from the State University of New York at Buffalo. He completed residency training in anatomical pathology at Cornell and clinical pathology at Mayo Clinic. After 10 years of experience as a clinical pathologist and Chief of Laboratory Service at the Buffalo Veterans Administration Medical Center, he joined the Division of Clinical Laboratory Devices at the FDA as a medical officer in 1992. Dr. Gutman was promoted to division director in 1993. In November 2002, he became director of the Office of In Vitro Diagnostic Device Evaluation and Safety, a new office in the FDA's Center for Devices and Radiological Health. From January 2009 to December 2009 he worked as founding faculty of the University of Central Florida College of Medicine. In January 2010 Dr. Gutman became an associate director of the BlueCross BlueShield Association Technology Evaluation Center. In January 2013 he became strategic advisor for Myraqa, Inc., a regulatory consulting firm specializing in in vitro diagnostic devices.
Peter Kuhn, PhD
Dean’s Professor of Convergent Science, USC Dornsife
Associate Professor of Cell & Molecular Biology, The Scripps Research Institute
Dr. Kuhn is a scientist and entrepreneur with a career long commitment in personalized medicine and individualized cancer patient care. He is focused on the redesign of cancer care.
Dr. Kuhn is the Dean’s Professor of Convergent Science at USC, a co-founder of the BRIDGE @ USC and director of the Southern California Physics Oncology Center. His research is shedding new light at how cancer spreads through the body. This new science will lead to a personalized care strategy that is biologically informed and clinically actionable.
Leveraging the laboratory’s fluid biopsy technology innovation, the Southern California Physics Oncology Center is advancing daily the forefront of both improving healthcare effectiveness for cancer patients by providing drug guidance and increasing our understanding of cancer as a disease in each individual patient. The technology developed in the academic laboratory has been licensed to Epic Sciences to bring to market high precision diagnostic products.
Dr. Kuhn is a physicist who trained initially at the Julius Maximilians Universität Würzburg, Germany, before receiving his Masters in Physics at the University of Albany, Albany, NY in 1993 and his Ph.D. in 1995. He then moved to Stanford University where he later joined the faculties of Medicine and Accelerator Physics. From 2002 to 2014 he established a translational science program at the Scripps Research in La Jolla, CA that brought together over forty scientists from basic, engineering and medical sciences to work on understanding the spread of cancer in the human body. He has published over 200 peer scientific articles and patents as a result of his research.
The University of Southern California (USC) recruited Dr. Kuhn in 2014 to advance the next frontier of human scale science that can improve the human condition. At the convergence of biological, engineering and medical sciences will we learn how major diseases from cancer to neurodegenerative to autoimmune diseases evolve in and how we can improve the outcomes for patients.
Joshua LaBaer, MD, PhD
Director, The Biodesign Institute’s Virginia G. Piper Chair of Personalized Medicine Professor, School of Liberal Arts and Sciences, Arizona State University
Formerly founder and director of the Harvard Institute of Proteomics, LaBaer was recruited to ASU’s Biodesign Institute as the first Piper Chair in Personalized Medicine in 2009.
Dr. LaBaer is one of the nation’s foremost investigators in the rapidly expanding field of personalized medicine. His efforts involve the discovery and validation of biomarkers, unique molecular fingerprints of disease, which can provide early warning for those at risk of major illnesses, including cancer and diabetes.
The Virginia G. Piper Center for Personalized Diagnostics (VGPCPD) has a highly multidisciplinary staff of molecular biologists, cell biologists, biochemists, software engineers, database specialists, bioinformaticists, biostatisticians, and automation engineers.
Dr. LaBaer was an early initiator and leader of the effort to build fully sequence-verified recombination-based clone sets for human genes and other model organisms now managed in an automated repository with more than 250,000 samples, which are openly shared with the scientific community. His laboratory has developed a number of methods to employ these clones, including HT protein expression and purification, and HT screens of ectopic protein expression in mammalian cells for relevant phenotypes. In addition, his group invented a novel protein microarray technology, Nucleic Acid Programmable Protein Array, which has been used widely for biomedical research, including the recent discovery of a panel of 28 autoantibody biomarkers that may aid the early diagnosis of breast cancer.
Dr. LaBaer completed both his medical internship and residency at the Brigham and Women’s Hospital and a clinical fellowship in oncology at the Dana-Farber Cancer Institute, both in Boston. He is a board-certified physician in internal medicine and medical oncology and was an instructor and clinical fellow in medicine at Harvard Medical School. He has contributed more than 120 original research publications, reviews, and chapters. He is a member of the National Cancer Institute’s Board of Scientific Advisors and serves as chair of the National Cancer Institute’s Early Detection Research Network Executive Committee and Co-Chair of its Steering Committee. He is a Research Affiliate with the Mayo Clinic and treasurer and president-elect of the U.S. Human Proteome Organization. Dr. LaBaer earned his medical degree and a doctorate in biochemistry and biophysics from the University of California, San Francisco.
Randall W. Nelson, PhD
Director of the Molecular Biomarkers Laboratory, The Biodesign Instutute, Arizona State University
Dr. Nelson directs the Molecular Biomarkers Laboratory (MBL) at the Biodesign Institute at Arizona State University and also holds the positions of Research Professor in the Biodesign and Affiliate Professor in the Department of Chemistry and Biochemistry. The Mission of the MBL is to “Improve human health through the greater understanding of protein behavior in healthy and disease populations.” To this end, the laboratory applies advanced mass spectrometric immunoassay (MSIA) technologies in the discovery and validation of changes in protein microheterogeneity related to disease (packaged as biosignatures), and translates these technologies and findings deeper into industry by establishing collaborative relationships. Dr. Nelson’s research is currently focused on understanding changes in biosignatures as an individual transits from healthy to Type 2 diabetes (T2D) to cardiovascular disease (CVD), research that is directed at integrating biosignatures into (T2D/CVD) drug discovery and is undertaken as part of a research network including the Veterans Administration, the University of Arizona, and pharmaceutical strategic partners such as Pfizer Inc.
Dr. Nelson received his doctorate in Analytical Chemistry from ASU in 1990 and has published more than 110 peer-reviewed manuscripts, and given more than 100 invited talks at national and international conferences, all regarding biological mass spectrometry and biomarker development/translation. He is inventor or co-inventor on 33 issued and 10 pending patents covering mass spectrometric technologies/methods and protein biosignatures related to disease. Prior to coming to the Biodesign Institute, Dr. Nelson founded and served as President and CEO of Intrinsic Bioprobes, Inc., a biotechnology startup company in Tempe, AZ, that specialized in MSIA technologies applied in biomarker development, which was recently (2011) acquired by Thermo Fisher Scientific (TMO). Presently, he consults or collaborates with TMO, SimulTOF Systems, Pfizer Inc., and Laboratory Corporation of America (LabCorp).
Robert Penny, MD, Ph.D.
CEO, International Genomics Consortium
Dr. Penny is the CEO of the International Genomics Consortium and also serves as a board member and Chief Medical Officer. He has leadership roles in the Cancer Genome Atlas project (TCGA) as the Principal Investigator for the Biospecimen Core Resource (BCR) and for TCGA’s Tissue Source Site network. He has created a world-class biorepository at IGC through their expression project for Oncology (expO), which is characterized both clinically with treatment and outcome data as well as molecularly. He has historical competencies in tissue and data standards to complement the high quality biospecimens that he has accrued.
Dr. Penny is one of the founders, CEO, and a board member of Paradigm, a new cutting-edge advanced diagnostics company that is bringing next generation sequencing and other technologies to personalized medicine. The company is located in Phoenix and Ann Arbor.
While at the IGC, he founded the Molecular Profiling Institute and served as its Chief Executive Officer and Chairman of the Board. The Molecular Profiling Institute is the first company to commercially introduce gene expression analysis into oncology in the U.S. He developed the Molecular Profiling Institute’s portfolio of molecular testing and pharmaceutical services which includes his successful commercially available holistic genomic analysis of cancer with its award-winning surgical oncology report (Target Now). He led the successful merger of the Molecular Profiling Institute into Caris Life Sciences.
Dr. Penny is a recognized expert in the translation of diagnostics into patient care as well as in biorepositories. He has established two national esoteric reference medical laboratories, a national tissue bank and analysis center, and a national genomics program. He has helped bring cellular and molecular diagnostic, prognostic, and therapeutic testing to patient care throughout the nation with leukemia, lymphoma, and solid tumors. He has headed up genomic strategies for one of the nation’s largest medical diagnostic corporations and chaired committees for TCGA leadership.
Dr. Penny received the College of American Pathologists’ 2012 Distinguished Patient Care Award. The College of American Pathologists honored Dr. Penny for his extensive scientific translational research to accelerate the adoption of molecular pathways and associated therapies into the field of pathology and oncology to improve the lives of cancer patients. In 2011, the AZ BioIndustry Association honored Dr. Penny with the Jon W. McGarity Leadership Award for his vision in advancing cancer personalized medicine and success in leading the industry.
Dr. Penny received his B.S., M.S., Ph.D. (Genetics), and M.D. from the University of Arizona and then went on to receive his pathology training at Harvard’s Brigham & Women’s Hospital in Boston, Massachusetts, where he served as Chief Resident and completed fellowships in hematopathology and surgical pathology. Dr. Penny currently is an Associate Professor at the University of Michigan. Dr. Penny’s contributions include a textbook in oncology, publication of articles and leadership roles in laboratory management.
John Quackenbush, Ph.D.
Professor of Biostatistics and Computational Biology & Professor of Cancer Biology, Dana-Farber Cancer Institute (DFCI)
Professor of Computational Biology and Bioinformatics, Harvard School of Public Health
John Quackenbush received his Ph.D. in 1990 in theoretical physics from UCLA working on string theory models. Following two years as a postdoctoral fellow in physics, Dr. Quackenbush applied for and received a Special Emphasis Research Career Award from the National Center for Human Genome Research to work on the Human Genome Project. He spent two years at the Salk Institute and two years at Stanford University working at the interface of genomics and computational biology. In 1997 he joined the faculty of The Institute for Genomic Research (TIGR) where his focus began to shift to understanding what was encoded within the human genome. Since joining the faculties of the Dana-Farber Cancer Institute and the Harvard School of Public Health in 2005, his work has focused on the use of genomic data to reconstruct the networks of genes that drive the development of diseases such as cancer and emphysema.
Daniel C. Sullivan, M.D.
Professor and Vice Chair for Research, Department of Radiology, Duke University Medical Center, and Science Advisor, Radiological Society of North America
Dr. Sullivan is Professor and Vice Chair for Research, Department of Radiology at Duke University Medical Center and also Science Adviser to the Radiological Society of North America (RSNA). He completed radiology residency and nuclear medicine fellowship in 1977 at Yale-New Haven Hospital. From 1977 to 1997 Dr. Sullivan was in academic radiology, holding faculty appointments at Yale University Medical Center, Duke University Medical Center, and University of Pennsylvania Medical Center, before joining the National Cancer Institute at NIH in 1997. From 1997 to 2007 Dr. Sullivan was Associate Director in the Division of Cancer Treatment and Diagnosis of the National Cancer Institute (NCI) and Head of the Cancer Imaging Program (CIP) at NCI. His areas of clinical and research expertise are in nuclear medicine and oncologic imaging, in particular focusing on improving the use of imaging as a biomarker in clinical trials and facilitating translational research involving new and established imaging methods. Dr. Sullivan’s current responsibilities at Duke include serving as co-director of the Radiation Oncology and Imaging Program for the Duke Comprehensive Cancer Center. In his role with the RSNA Dr. Sullivan founded and Chairs the Quantitative Imaging Biomarkers Alliance (QIBA), which coordinates a wide range of national and international activities related to the evaluation and validation of quantitative imaging biomarkers for clinical research and practice.
Anna D. Barker, PhD
President and Director, National Biomarker Development Alliance; Director, Transformative Healthcare Knowledge Networks; Co-Director, Complex Adaptive Systems; Professor, School of Life Sciences, Arizona State University
As the director and president of the NBDA, Dr. Barker leads the areas of strategic planning, staffing, program development, and implementation. She works closely with the management team, advisors, external experts, and other stakeholders to define the scope of targeted scientific and education projects and to achieve the mission of the NBDA.
Dr. Barker is co-director of Complex Adaptive Systems at Arizona State University (ASU), which serves as an organizing construct to understand and solve multidimensional problems in the biological and social and sciences, such as those represented by the NBDA. In this role, she has directed efforts to develop transformative knowledge networks that leverage convergent knowledge, innovative teams, and novel funding approaches to better prevent and treat acute and chronic diseases. The NBDA will employ this model.
Prior to joining ASU, Dr. Barker served as deputy director of the NCI and as deputy director of the NCI’s Strategic Scientific Initiatives for several years, where she developed and implemented multidisciplinary and transdisciplinary programs, including the Nanotechnology Alliance for Cancer, The Cancer Genome Atlas (TCGA) (in collaboration with the National Human Genome Research Institute), the Clinical Proteomics Technologies Initiative for Cancer, the Physical Sciences-Oncology Centers, and major national efforts in biospecimen best practices (caHUB) and bioinformatics (caBIG). All of these programs emphasize the synergy of large-scale and individual-initiated research, precompetitive research, public databases, and clinical research to more effectively detect, prevent, and treat cancer. She also oversaw the NCI’s international cancer research programs, including pilot programs in Latin America and China.
In the biomarker area, Dr. Barker was the founding co-chair of the NCI-FDA Interagency Task Force, founding co-chair of the Cancer Steering Committee of the Foundation for the National Institutes of Health (FNIH) Biomarker Consortium, and founding director of the NBDA. She has a long history in research and in the leadership and management of research and development in the academic, nonprofit, and private sectors. Dr. Barker served as a senior scientist and subsequently as a senior executive at Battelle Memorial Institute for 18 years and cofounded and served as the CEO of a public biotechnology drug development company. She has received a number of awards for her work in support of cancer research, cancer patients, professional and advocacy organizations, and the ongoing national effort to prevent and cure cancer. Dr. Barker’s research interests include biomarker discovery and development, complex adaptive systems science, and free-radical biochemistry in cancer etiology and treatment. She completed her M.A. and Ph.D. degrees at The Ohio State University, where she trained in immunology and microbiology.
Carolyn Compton, MD, PhD
Chief Medical Officer, National Biomarker Development Alliance, Professor, School of Life Sciences, Arizona State University
As chief medical officer of the NBDA, Dr. Compton works closely with transsector external experts on all phases of specific network-enabled projects to address major barriers in the biomarker development process. In this role she plans and implements consensus conferences and prioritizes and integrates existing guidelines, best practices, and other standards to identify targeted needs for demonstration projects and new research. Dr. Compton also leads the NBDA’s programs in biospecimens and biorepositories and implements specific programs that include clinical trials.
She is a nationally prominent academic pathologist specializing in gastrointestinal disease and is board certified in both anatomic and clinical pathology. Dr. Compton is a Professor at ASU and an adjunct Professor of Pathology at both the University of Arizona and Johns Hopkins. At ASU she is on the faculty of the School of Life Sciences, and at Mayo Clinic she is a research affiliate in the Department of Pathology and Laboratory Medicine.
Dr. Compton is a member of The Biodesign Institute and the Complex Adaptive Systems Initiative. She is a former Professor of Pathology at Harvard Medical School, Chief of Gastrointestinal Pathology at Massachusetts General Hospital, and Pathologist-in-Chief at Boston Shriners Children’s Hospital. More recently she has served as the CEO and President of the Critical Path Institute (2012), director of Biorespositories and Biospecimen Research and the Innovative Molecular Analysis Technologies program at the NCI (2005-2011), the Strathcona Professor and Chair of the Department of Pathology at McGill University, and Pathologist-in-Chief of the McGill University Health Center (2000-2005). Dr. Compton is immediate past chair of the American Joint Committee on Cancer (AJCC) and chair of the AJCC’s Precision Medicine Core. She has authored more than 500 scientific manuscripts, review articles, books, and chapters. Dr. Compton received her M.D. and Ph.D. degrees from Harvard University.
George Poste, DVM PhD
Interim Chief Science Officer, National Biomarker Development Alliance; Co-Director, Complex Adaptive Systems; Regents’ Professor and Del E. Webb Chair in Health Innovation, Arizona State University
Dr. Poste serves as the interim Chief Science Officer for the NBDA. In this role, through the NBDA’s think tanks and workshops and literature and other sources, he works closely with the Alliance team to identify and prioritize key barriers in the discovery and development modules of biomarker development. He also creates networks among relevant stakeholders to plan and implement solution strategies for the barriers identified.
Dr. Poste is Regents’ Professor and Del E. Webb Chair of Health Innovation at Arizona State University. He founded and built the Biodesign Institute at ASU and served as its Director from 2003 to 2009. In 2009 he launched the Complex Adaptive Systems (CAS) at ASU which integrates research across disciplines to study the altered regulation of molecular networks in human diseases to provide a contemporary basis for the development of targeted disease interventions, inclusive of remote monitoring of health status using miniaturized body sensors and mobile devices.
Dr. Poste is a Fellow of the U.K. Royal Society, the Royal College of Pathologists, and the U.K. Academy of Medicine; a Distinguished Fellow at the Hoover Institution, Stanford University; and a member of the Council on Foreign Relations and the U.S. Institute of Medicine Board on Global Health. He has served as a member of the Defense Science Board of the U.S. Department of Defense and currently serves on advisory committees for several U.S. government agencies in defense, intelligence, national security, and health care.
He has published extensively on pharmaceutical technologies, cancer, and infectious diseases. He was honored in 1999 by Her Majesty, Queen Elizabeth II, as a Commander of the British Empire for his contributions to international health care and security. He serves on the Board of Directors of Monsanto, Exelixis, Caris Life Sciences, and the Scientific Advisory Boards of Burrill and Company and Synthetic Genomics. From 1992 to 1999, he was Chief Science and Technology Officer and President, R&D, of SmithKline Beecham (SB), where he was associated with the registration of 31 drug, vaccine, and diagnostic products. He has received a number of awards, including Scientist of the Year by R&D Magazine; the Einstein Award from the Global Business Leadership Council, 2006; and the Scrip Lifetime Achievement Award, 2009.